tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

CRNX Stock Latest News

Crinetics Pharmaceuticals: Promising Pipeline and Strategic Positioning Justify Buy Rating
RatingsCrinetics Pharmaceuticals: Promising Pipeline and Strategic Positioning Justify Buy Rating
8d ago
CRNX
Crinetics treatment of carcinoid syndrome granted FDA orphan status
PremiumThe Fly
Crinetics treatment of carcinoid syndrome granted FDA orphan status
22d ago
CRNX
Optimistic Growth Outlook for Crinetics Pharmaceuticals Amidst Strategic Advances and Strong Financial Position
PremiumRatings
Optimistic Growth Outlook for Crinetics Pharmaceuticals Amidst Strategic Advances and Strong Financial Position
24d ago
CRNX
Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges
PremiumCompany Announcements
Crinetics Pharma’s Earnings Call: Positive Outlook Amid Challenges
28d ago
CRNX
Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating
PremiumRatings
Crinetics Pharmaceuticals: Strong Financial Position and Promising Pipeline Drive Buy Rating
29d ago
CRNX
Buy Rating Affirmed for Crinetics Pharmaceuticals: Promising Phase 3 Trial of Atumelnant for CAH
PremiumRatingsBuy Rating Affirmed for Crinetics Pharmaceuticals: Promising Phase 3 Trial of Atumelnant for CAH
29d ago
CRNX
Crinetics Pharmaceuticals Reports Q1 2025 Financial Results
Premium
Company Announcements
Crinetics Pharmaceuticals Reports Q1 2025 Financial Results
29d ago
CRNX
Crinetics Pharmaceuticals: Promising Outlook with Paltusotine Approval and Strategic Market Positioning
Premium
Ratings
Crinetics Pharmaceuticals: Promising Outlook with Paltusotine Approval and Strategic Market Positioning
29d ago
CRNX
Crinetics reports Q1 EPS ($1.04), consensus (95c)
PremiumThe Fly
Crinetics reports Q1 EPS ($1.04), consensus (95c)
29d ago
CRNX
Crinetics gets EMA approval for paltusotine marketing authorization application
PremiumThe Fly
Crinetics gets EMA approval for paltusotine marketing authorization application
2M ago
CRNX
Crinetics initiated with a Buy at Stifel
PremiumThe Fly
Crinetics initiated with a Buy at Stifel
2M ago
CRNX
Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals
PremiumRatings
Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals
3M ago
CRNX
Crinetics Pharma’s Earnings Call: Progress Amid Challenges
PremiumCompany AnnouncementsCrinetics Pharma’s Earnings Call: Progress Amid Challenges
3M ago
CRNX
Crinetics Pharmaceuticals: Promising Transition to Commercialization Amidst Safety Concerns and Strategic Market Positioning
Premium
Ratings
Crinetics Pharmaceuticals: Promising Transition to Commercialization Amidst Safety Concerns and Strategic Market Positioning
3M ago
CRNX
Crinetics Pharmaceuticals: Promising Developments and Strategic Initiatives Underpin Buy Rating
Premium
Ratings
Crinetics Pharmaceuticals: Promising Developments and Strategic Initiatives Underpin Buy Rating
3M ago
CRNX
Crinetics price target lowered to $91 from $92 at Citizens JMP
PremiumThe Fly
Crinetics price target lowered to $91 from $92 at Citizens JMP
3M ago
CRNX
Crinetics Pharmaceuticals: Buy Rating Backed by Promising Pipeline and Strategic Growth Plans
PremiumRatings
Crinetics Pharmaceuticals: Buy Rating Backed by Promising Pipeline and Strategic Growth Plans
3M ago
CRNX
Crinetics price target lowered to $68 from $74 at Citi
PremiumThe Fly
Crinetics price target lowered to $68 from $74 at Citi
3M ago
CRNX
Crinetics Pharmaceuticals: Promising Future with Paltusotine Launch and Robust Pipeline Development
PremiumRatings
Crinetics Pharmaceuticals: Promising Future with Paltusotine Launch and Robust Pipeline Development
3M ago
CRNX
Crinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials
PremiumRatingsCrinetics Pharmaceuticals: Positioned for Growth with Promising Drug Pipeline and Strong Financials
3M ago
CRNX
Crinetics Pharmaceuticals: Financial Results and Future Plans
Premium
Company Announcements
Crinetics Pharmaceuticals: Financial Results and Future Plans
3M ago
CRNX
Crinetics reports Q4 EPS (88c), consensus (89c)
Premium
The Fly
Crinetics reports Q4 EPS (88c), consensus (89c)
3M ago
CRNX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >